Company news

HBM Holdings Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Next Day Disclosure Return

October 30, 2026

Next Day Disclosure Return

October 27, 2026

Inside information announcement - nmpa approval of batoclimab injection (subcutaneous injection) for the treatment of generalized myasthenia gravis

October 22, 2026

Next Day Disclosure Return

October 20, 2026

Next Day Disclosure Return

October 16, 2026

Next Day Disclosure Return

October 15, 2026

Next Day Disclosure Return

October 14, 2026

Next Day Disclosure Return

October 13, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 7, 2026

Supplemental announcement in relation to the 2025 annual report and the 2026 interim report

September 21, 2026

Voluntary announcement - nona biosciences develops the world's first language model trained on fully human heavy-chain-only antibodies

September 16, 2026

Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors

May 8, 2026

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

March 9, 2026

Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results

February 3, 2026

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

January 18, 2026

Control Devices Acquires Sherwood Valve

January 12, 2026

Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

December 28, 2025

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

December 16, 2025

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

November 23, 2025

Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development

November 7, 2025

Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery

October 28, 2025

Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC

October 21, 2025

Harbour BioMed Reports 2025 Interim Results

August 27, 2025

Harbour BioMed Appoints Yajie Li as Chief Medical Officer

August 24, 2025

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

July 29, 2025

Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results

July 27, 2025

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

July 23, 2025

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

June 22, 2025

China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward

June 16, 2025

Harbour BioMed Appoints Youchen Chen as Chief Financial Officer

April 9, 2025

Harbour BioMed Reports Full Year 2024 Financial Results

March 31, 2025

Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies

March 21, 2025

Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies

March 12, 2025

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer

March 9, 2025

Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

March 9, 2025

Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development

February 20, 2025

Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

July 18, 2024

Harbour BioMed Reports Full Year 2023 Financial Results

March 28, 2024

Harbour BioMed Announces Positive Profit Alert

January 18, 2024

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

August 8, 2023

Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation

July 13, 2023

Harbour BioMed Reports Full Year 2022 Financial Results

April 3, 2023

HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders

January 25, 2023

Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

November 10, 2022

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

May 4, 2022

Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022

April 6, 2022

Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities

March 24, 2022

Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

January 4, 2022

Harbour BioMed: Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003

September 14, 2021

Voluntary announcement - dosing of first patient in phase ib/IIa clinical study of next-generation anti-ctla-4 antibody in australia

May 12, 2021

Decks

The 5 newest of 9 decks. Every deck is listed under its year.